Rifapentine
From Wikipedia, the free encyclopedia
 |
|
|
Rifapentine
|
|
| Systematic (IUPAC) name | |
| 3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin | |
| Identifiers | |
| CAS number | |
| ATC code | J04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C47H64N4O12 |
| Mol. mass | 877.031 g/mol |
| Pharmacokinetic data | |
| Bioavailability | increases when administered with food |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Rifapentine (INN, marketed under the brand name Priftin by Aventis) is an antibiotic drug used in the treatment of tuberculosis.
[edit] History
Rifapentine was first synthesized in 1965 by the same company that produced rifampin. The drug was approved by the Food and Drug Administration (FDA) in June 1998.
[edit] External links
- Rosenthal IM, Zhang M, Williams KN, et al (December 2007). "Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model". PLoS Medicine 4 (12): e344. doi:. PMID 18092886.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
